nodes	percent_of_prediction	percent_of_DWPC	metapath
Rasagiline—CYP1A2—Progesterone—uterine cancer	0.0687	0.691	CbGbCtD
Rasagiline—CYP1A2—Etoposide—uterine cancer	0.0308	0.309	CbGbCtD
Rasagiline—BCL2—epithelium—uterine cancer	0.0103	0.0944	CbGeAlD
Rasagiline—BCL2—smooth muscle tissue—uterine cancer	0.00992	0.0909	CbGeAlD
Rasagiline—BCL2—renal system—uterine cancer	0.00955	0.0875	CbGeAlD
Rasagiline—BCL2—endometrium—uterine cancer	0.00923	0.0846	CbGeAlD
Rasagiline—BCL2—uterus—uterine cancer	0.00851	0.078	CbGeAlD
Rasagiline—BCL2—female reproductive system—uterine cancer	0.00765	0.0701	CbGeAlD
Rasagiline—BCL2—female gonad—uterine cancer	0.00696	0.0638	CbGeAlD
Rasagiline—MAOB—myometrium—uterine cancer	0.00546	0.0501	CbGeAlD
Rasagiline—BCL2—lymph node—uterine cancer	0.00447	0.041	CbGeAlD
Rasagiline—MAOB—uterine cervix—uterine cancer	0.00425	0.039	CbGeAlD
Rasagiline—MAOB—decidua—uterine cancer	0.00405	0.0371	CbGeAlD
Rasagiline—MAOB—renal system—uterine cancer	0.00398	0.0364	CbGeAlD
Rasagiline—MAOB—endometrium—uterine cancer	0.00384	0.0352	CbGeAlD
Rasagiline—MAOB—mammalian vulva—uterine cancer	0.00372	0.0341	CbGeAlD
Rasagiline—MAOB—uterus—uterine cancer	0.00354	0.0325	CbGeAlD
Rasagiline—MAOB—female reproductive system—uterine cancer	0.00318	0.0292	CbGeAlD
Rasagiline—MAOB—female gonad—uterine cancer	0.0029	0.0266	CbGeAlD
Rasagiline—MAOB—vagina—uterine cancer	0.00288	0.0264	CbGeAlD
Rasagiline—CYP1A2—renal system—uterine cancer	0.00283	0.0259	CbGeAlD
Rasagiline—MAOB—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.00255	0.0105	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—PMS2—uterine cancer	0.00249	0.0102	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—SMAD3—uterine cancer	0.00236	0.00967	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—SOCS3—uterine cancer	0.00229	0.00939	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—BIRC5—uterine cancer	0.00223	0.00914	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—IRF1—uterine cancer	0.0022	0.00899	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—CYP11A1—uterine cancer	0.00217	0.0089	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—SOCS3—uterine cancer	0.00214	0.00875	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TNFSF10—uterine cancer	0.00198	0.00809	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—MSH6—uterine cancer	0.00194	0.00795	CbGpPWpGaD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—CDKN2B—uterine cancer	0.00194	0.00795	CbGpPWpGaD
Rasagiline—MAOB—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.00188	0.00769	CbGpPWpGaD
Rasagiline—MAOB—lymph node—uterine cancer	0.00186	0.0171	CbGeAlD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—TNFSF10—uterine cancer	0.00185	0.00759	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—IRF1—uterine cancer	0.00184	0.00752	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—HMGA1—uterine cancer	0.0018	0.00737	CbGpPWpGaD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—SMAD3—uterine cancer	0.00177	0.00726	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—MSH2—uterine cancer	0.00167	0.00685	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—INHBA—uterine cancer	0.00165	0.00676	CbGpPWpGaD
Rasagiline—BCL2—Activation of BAD and translocation to mitochondria—AKT1—uterine cancer	0.00164	0.00673	CbGpPWpGaD
Rasagiline—BCL2—TP53 Network—TP53—uterine cancer	0.00161	0.0066	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—MSH2—uterine cancer	0.00157	0.00645	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—ESR1—uterine cancer	0.00152	0.00624	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—MLH1—uterine cancer	0.00151	0.00618	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—IGF1R—uterine cancer	0.0015	0.00613	CbGpPWpGaD
Rasagiline—BCL2—Estrogen signaling pathway—PIK3CA—uterine cancer	0.00143	0.00585	CbGpPWpGaD
Rasagiline—MAOB—Biological oxidations—CYP11A1—uterine cancer	0.00136	0.00555	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—BIRC5—uterine cancer	0.00133	0.00545	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—CDKN1B—uterine cancer	0.00131	0.00536	CbGpPWpGaD
Rasagiline—BCL2—Activation of BH3-only proteins—TP53—uterine cancer	0.00129	0.0053	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—YWHAE—uterine cancer	0.00126	0.00515	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—IGF1R—uterine cancer	0.00125	0.00513	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—BIRC5—uterine cancer	0.00125	0.00511	CbGpPWpGaD
Rasagiline—BCL2—IL-3 Signaling Pathway—CXCL8—uterine cancer	0.00123	0.00504	CbGpPWpGaD
Rasagiline—CYP1A2—Estrogen Receptor Pathway—ESR1—uterine cancer	0.00122	0.00499	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TNFSF10—uterine cancer	0.00121	0.00496	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—PTEN—uterine cancer	0.00121	0.00494	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—SMAD3—uterine cancer	0.00118	0.00482	CbGpPWpGaD
Rasagiline—BCL2—Estrogen signaling pathway—AKT1—uterine cancer	0.00117	0.00478	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by STAT5—PIK3CA—uterine cancer	0.00116	0.00473	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—SMAD3—uterine cancer	0.00114	0.00468	CbGpPWpGaD
Rasagiline—BCL2—Activation of BH3-only proteins—AKT1—uterine cancer	0.00109	0.00447	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CYP19A1—uterine cancer	0.00108	0.00441	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—STK11—uterine cancer	0.00108	0.00441	CbGpPWpGaD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—PTEN—uterine cancer	0.00107	0.00439	CbGpPWpGaD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—ERBB2—uterine cancer	0.00106	0.00435	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—CXCL8—uterine cancer	0.00106	0.00434	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	0.00106	0.00434	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NFE2L2—uterine cancer	0.00102	0.00417	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—NFE2L2—uterine cancer	0.00102	0.00417	CbGpPWpGaD
Rasagiline—BCL2—EPO signaling pathway—HRAS—uterine cancer	0.00102	0.00416	CbGpPWpGaD
Rasagiline—BCL2—IL-5 Signaling Pathway—KRAS—uterine cancer	0.000999	0.00409	CbGpPWpGaD
Rasagiline—MAOB—Biological oxidations—CYP19A1—uterine cancer	0.000998	0.00409	CbGpPWpGaD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—CDKN1B—uterine cancer	0.000983	0.00403	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	0.000981	0.00402	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by PI3K—PIK3CA—uterine cancer	0.000977	0.004	CbGpPWpGaD
Rasagiline—BCL2—Role of Calcineurin-dependent NFAT signaling in lymphocytes—EP300—uterine cancer	0.000976	0.004	CbGpPWpGaD
Rasagiline—BCL2—Intrinsic Pathway for Apoptosis—TP53—uterine cancer	0.000925	0.00379	CbGpPWpGaD
Rasagiline—BCL2—Amyotrophic lateral sclerosis (ALS)—TP53—uterine cancer	0.000925	0.00379	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—NRAS—uterine cancer	0.000913	0.00374	CbGpPWpGaD
Rasagiline—BCL2—Kit receptor signaling pathway—EP300—uterine cancer	0.000909	0.00373	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—EP300—uterine cancer	0.000909	0.00373	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	0.000891	0.00365	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—CDKN2A—uterine cancer	0.000881	0.00361	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—CDKN2A—uterine cancer	0.000881	0.00361	CbGpPWpGaD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—EP300—uterine cancer	0.000863	0.00353	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—CDKN2A—uterine cancer	0.000827	0.00339	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—TP53—uterine cancer	0.000823	0.00337	CbGpPWpGaD
Rasagiline—BCL2—IL-2 Signaling Pathway—HRAS—uterine cancer	0.000817	0.00335	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	0.000799	0.00327	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by PI3K—AKT1—uterine cancer	0.000798	0.00327	CbGpPWpGaD
Rasagiline—CYP1A2—Arachidonic acid metabolism—AKR1C3—uterine cancer	0.000796	0.00326	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—HRAS—uterine cancer	0.000787	0.00322	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—KRAS—uterine cancer	0.000786	0.00322	CbGpPWpGaD
Rasagiline—BCL2—Intrinsic Pathway for Apoptosis—AKT1—uterine cancer	0.000781	0.0032	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—CDKN1B—uterine cancer	0.000781	0.0032	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—IGF1R—uterine cancer	0.000779	0.00319	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—MET—uterine cancer	0.000766	0.00314	CbGpPWpGaD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—PIK3CA—uterine cancer	0.000756	0.0031	CbGpPWpGaD
Rasagiline—BCL2—IL-5 Signaling Pathway—AKT1—uterine cancer	0.00075	0.00307	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—CXCL8—uterine cancer	0.000743	0.00304	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—CDKN2A—uterine cancer	0.000737	0.00302	CbGpPWpGaD
Rasagiline—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000729	0.00299	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—PIK3CA—uterine cancer	0.000722	0.00296	CbGpPWpGaD
Rasagiline—BCL2—IL-3 Signaling Pathway—HRAS—uterine cancer	0.000722	0.00296	CbGpPWpGaD
Rasagiline—BCL2—IL-2 Signaling Pathway—AKT1—uterine cancer	0.000721	0.00295	CbGpPWpGaD
Rasagiline—CYP1A2—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000719	0.00295	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—ESR1—uterine cancer	0.000718	0.00294	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CDKN2A—uterine cancer	0.000716	0.00293	CbGpPWpGaD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—HRAS—uterine cancer	0.000699	0.00286	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—AKT1—uterine cancer	0.000695	0.00285	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—AKT1—uterine cancer	0.000695	0.00285	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—CTNNB1—uterine cancer	0.000686	0.00281	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—EP300—uterine cancer	0.000685	0.00281	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—ERBB2—uterine cancer	0.000684	0.0028	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—CXCL8—uterine cancer	0.000669	0.00274	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—HRAS—uterine cancer	0.000668	0.00274	CbGpPWpGaD
Rasagiline—CYP1A2—Tryptophan metabolism—CYP19A1—uterine cancer	0.000663	0.00272	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—CDKN1B—uterine cancer	0.000653	0.00267	CbGpPWpGaD
Rasagiline—BCL2—Ceramide signaling pathway—AKT1—uterine cancer	0.000648	0.00266	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—NRAS—uterine cancer	0.000641	0.00263	CbGpPWpGaD
Rasagiline—BCL2—IL-3 Signaling Pathway—AKT1—uterine cancer	0.000638	0.00261	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CDKN1B—uterine cancer	0.000634	0.0026	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CDH1—uterine cancer	0.000625	0.00256	CbGpPWpGaD
Rasagiline—BCL2—Kit receptor signaling pathway—HRAS—uterine cancer	0.000622	0.00255	CbGpPWpGaD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—AKT1—uterine cancer	0.000617	0.00253	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—CDH1—uterine cancer	0.000612	0.00251	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—PTEN—uterine cancer	0.000601	0.00246	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—MET—uterine cancer	0.0006	0.00246	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CTNNB1—uterine cancer	0.000599	0.00245	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	0.000595	0.00244	CbGpPWpGaD
Rasagiline—CYP1A2—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000591	0.00242	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—PTEN—uterine cancer	0.000584	0.00239	CbGpPWpGaD
Rasagiline—BCL2—Caspase Cascade in Apoptosis—AKT1—uterine cancer	0.000565	0.00231	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—AKR1B10—uterine cancer	0.000556	0.00228	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—KRAS—uterine cancer	0.000552	0.00226	CbGpPWpGaD
Rasagiline—BCL2—Kit receptor signaling pathway—AKT1—uterine cancer	0.00055	0.00225	CbGpPWpGaD
Rasagiline—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000536	0.0022	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—NDUFB11—uterine cancer	0.000536	0.0022	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—SRD5A2—uterine cancer	0.000536	0.0022	CbGpPWpGaD
Rasagiline—CYP1A2—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.000529	0.00217	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—NRAS—uterine cancer	0.000521	0.00213	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—AKR1B1—uterine cancer	0.000517	0.00212	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TP53—uterine cancer	0.000491	0.00201	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—PTEN—uterine cancer	0.000478	0.00196	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—IRF1—uterine cancer	0.00047	0.00192	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—HRAS—uterine cancer	0.000469	0.00192	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CTNNB1—uterine cancer	0.000461	0.00189	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—TP53—uterine cancer	0.00046	0.00188	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—EP300—uterine cancer	0.000456	0.00187	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—CTNNB1—uterine cancer	0.000452	0.00185	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—PTEN—uterine cancer	0.00045	0.00184	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—KRAS—uterine cancer	0.000448	0.00184	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—uterine cancer	0.000443	0.00181	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—ERBB2—uterine cancer	0.000439	0.0018	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	0.000437	0.00179	CbGpPWpGaD
Rasagiline—CYP1A2—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.000435	0.00178	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—EP300—uterine cancer	0.000429	0.00176	CbGpPWpGaD
Rasagiline—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000417	0.000762	CcSEcCtD
Rasagiline—Affect lability—Epirubicin—uterine cancer	0.000416	0.00076	CcSEcCtD
Rasagiline—Migraine—Epirubicin—uterine cancer	0.000416	0.00076	CcSEcCtD
Rasagiline—Dermatitis exfoliative—Doxorubicin—uterine cancer	0.000414	0.000757	CcSEcCtD
Rasagiline—BCL2—Apoptosis—AKT1—uterine cancer	0.000414	0.0017	CbGpPWpGaD
Rasagiline—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000414	0.000756	CcSEcCtD
Rasagiline—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000413	0.000755	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—PIK3CA—uterine cancer	0.000412	0.00169	CbGpPWpGaD
Rasagiline—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000411	0.000751	CcSEcCtD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—TP53—uterine cancer	0.00041	0.00168	CbGpPWpGaD
Rasagiline—Malaise—Etoposide—uterine cancer	0.000409	0.000748	CcSEcCtD
Rasagiline—Dermatitis bullous—Doxorubicin—uterine cancer	0.000409	0.000747	CcSEcCtD
Rasagiline—Face oedema—Epirubicin—uterine cancer	0.000408	0.000745	CcSEcCtD
Rasagiline—Vertigo—Etoposide—uterine cancer	0.000408	0.000745	CcSEcCtD
Rasagiline—Leukopenia—Etoposide—uterine cancer	0.000406	0.000742	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—VEGFA—uterine cancer	0.000406	0.00166	CbGpPWpGaD
Rasagiline—Purpura—Doxorubicin—uterine cancer	0.000406	0.000741	CcSEcCtD
Rasagiline—Abdominal pain—Dactinomycin—uterine cancer	0.000405	0.000739	CcSEcCtD
Rasagiline—Body temperature increased—Dactinomycin—uterine cancer	0.000405	0.000739	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	0.000405	0.00166	CbGpPWpGaD
Rasagiline—Cardiac failure—Doxorubicin—uterine cancer	0.000401	0.000732	CcSEcCtD
Rasagiline—Mood swings—Epirubicin—uterine cancer	0.0004	0.000731	CcSEcCtD
Rasagiline—Loss of consciousness—Etoposide—uterine cancer	0.000399	0.000729	CcSEcCtD
Rasagiline—Cerebrovascular accident—Doxorubicin—uterine cancer	0.000399	0.000729	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—TP53—uterine cancer	0.000398	0.00163	CbGpPWpGaD
Rasagiline—Ataxia—Epirubicin—uterine cancer	0.000397	0.000726	CcSEcCtD
Rasagiline—Cough—Etoposide—uterine cancer	0.000396	0.000724	CcSEcCtD
Rasagiline—Convulsion—Etoposide—uterine cancer	0.000393	0.000719	CcSEcCtD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—HRAS—uterine cancer	0.000392	0.00161	CbGpPWpGaD
Rasagiline—Hypertension—Etoposide—uterine cancer	0.000392	0.000716	CcSEcCtD
Rasagiline—Osteoarthritis—Doxorubicin—uterine cancer	0.000391	0.000714	CcSEcCtD
Rasagiline—Gastrointestinal haemorrhage—Doxorubicin—uterine cancer	0.000391	0.000714	CcSEcCtD
Rasagiline—Diplopia—Doxorubicin—uterine cancer	0.000391	0.000714	CcSEcCtD
Rasagiline—Liver function test abnormal—Epirubicin—uterine cancer	0.00039	0.000713	CcSEcCtD
Rasagiline—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.00039	0.000712	CcSEcCtD
Rasagiline—MAOB—Metabolism—STAR—uterine cancer	0.000388	0.00159	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—AKR1B1—uterine cancer	0.000388	0.00159	CbGpPWpGaD
Rasagiline—Chest pain—Etoposide—uterine cancer	0.000386	0.000706	CcSEcCtD
Rasagiline—Orthostatic hypotension—Epirubicin—uterine cancer	0.000386	0.000705	CcSEcCtD
Rasagiline—BCL2—Corticotropin-releasing hormone—AKT1—uterine cancer	0.000385	0.00158	CbGpPWpGaD
Rasagiline—Migraine—Doxorubicin—uterine cancer	0.000385	0.000703	CcSEcCtD
Rasagiline—Affect lability—Doxorubicin—uterine cancer	0.000385	0.000703	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—CTNNB1—uterine cancer	0.000384	0.00157	CbGpPWpGaD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000384	0.000701	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	0.000382	0.00157	CbGpPWpGaD
Rasagiline—Discomfort—Etoposide—uterine cancer	0.000382	0.000698	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—HRAS—uterine cancer	0.000381	0.00156	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—AKR1C1—uterine cancer	0.00038	0.00156	CbGpPWpGaD
Rasagiline—Face oedema—Doxorubicin—uterine cancer	0.000377	0.00069	CcSEcCtD
Rasagiline—Hypersensitivity—Dactinomycin—uterine cancer	0.000377	0.000689	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—PTEN—uterine cancer	0.000374	0.00153	CbGpPWpGaD
Rasagiline—Confusional state—Etoposide—uterine cancer	0.000374	0.000683	CcSEcCtD
Rasagiline—Muscular weakness—Epirubicin—uterine cancer	0.000373	0.000681	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	0.000373	0.00153	CbGpPWpGaD
Rasagiline—Mood swings—Doxorubicin—uterine cancer	0.00037	0.000677	CcSEcCtD
Rasagiline—Infection—Etoposide—uterine cancer	0.000368	0.000673	CcSEcCtD
Rasagiline—Ataxia—Doxorubicin—uterine cancer	0.000368	0.000672	CcSEcCtD
Rasagiline—Asthenia—Dactinomycin—uterine cancer	0.000367	0.000671	CcSEcCtD
Rasagiline—Influenza—Epirubicin—uterine cancer	0.000365	0.000667	CcSEcCtD
Rasagiline—Dysphagia—Epirubicin—uterine cancer	0.000365	0.000667	CcSEcCtD
Rasagiline—Asthma—Epirubicin—uterine cancer	0.000365	0.000667	CcSEcCtD
Rasagiline—Liver function test abnormal—Doxorubicin—uterine cancer	0.000361	0.00066	CcSEcCtD
Rasagiline—Skin disorder—Etoposide—uterine cancer	0.00036	0.000658	CcSEcCtD
Rasagiline—Hyperhidrosis—Etoposide—uterine cancer	0.000358	0.000654	CcSEcCtD
Rasagiline—Orthostatic hypotension—Doxorubicin—uterine cancer	0.000357	0.000652	CcSEcCtD
Rasagiline—Angina pectoris—Epirubicin—uterine cancer	0.000356	0.00065	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	0.000355	0.00146	CbGpPWpGaD
Rasagiline—Anorexia—Etoposide—uterine cancer	0.000353	0.000645	CcSEcCtD
Rasagiline—Diarrhoea—Dactinomycin—uterine cancer	0.00035	0.00064	CcSEcCtD
Rasagiline—Hypotension—Etoposide—uterine cancer	0.000346	0.000633	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—KRAS—uterine cancer	0.000345	0.00141	CbGpPWpGaD
Rasagiline—Muscular weakness—Doxorubicin—uterine cancer	0.000345	0.00063	CcSEcCtD
Rasagiline—Dysuria—Epirubicin—uterine cancer	0.000341	0.000624	CcSEcCtD
Rasagiline—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000339	0.00062	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—VEGFA—uterine cancer	0.000338	0.00138	CbGpPWpGaD
Rasagiline—Influenza—Doxorubicin—uterine cancer	0.000338	0.000617	CcSEcCtD
Rasagiline—Asthma—Doxorubicin—uterine cancer	0.000338	0.000617	CcSEcCtD
Rasagiline—Dysphagia—Doxorubicin—uterine cancer	0.000338	0.000617	CcSEcCtD
Rasagiline—Pollakiuria—Epirubicin—uterine cancer	0.000337	0.000616	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	0.000337	0.00138	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—AKT1—uterine cancer	0.000336	0.00138	CbGpPWpGaD
Rasagiline—Photosensitivity reaction—Epirubicin—uterine cancer	0.000333	0.000609	CcSEcCtD
Rasagiline—CYP1A2—Metapathway biotransformation—GPX3—uterine cancer	0.000333	0.00137	CbGpPWpGaD
Rasagiline—Paraesthesia—Etoposide—uterine cancer	0.000333	0.000608	CcSEcCtD
Rasagiline—Weight decreased—Epirubicin—uterine cancer	0.00033	0.000604	CcSEcCtD
Rasagiline—Dyspnoea—Etoposide—uterine cancer	0.00033	0.000604	CcSEcCtD
Rasagiline—Somnolence—Etoposide—uterine cancer	0.000329	0.000602	CcSEcCtD
Rasagiline—Angina pectoris—Doxorubicin—uterine cancer	0.000329	0.000601	CcSEcCtD
Rasagiline—BCL2—Direct p53 effectors—TP53—uterine cancer	0.000326	0.00134	CbGpPWpGaD
Rasagiline—Infestation NOS—Epirubicin—uterine cancer	0.000326	0.000595	CcSEcCtD
Rasagiline—Infestation—Epirubicin—uterine cancer	0.000326	0.000595	CcSEcCtD
Rasagiline—Vomiting—Dactinomycin—uterine cancer	0.000325	0.000595	CcSEcCtD
Rasagiline—Rash—Dactinomycin—uterine cancer	0.000323	0.00059	CcSEcCtD
Rasagiline—Decreased appetite—Etoposide—uterine cancer	0.000322	0.000588	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Etoposide—uterine cancer	0.00032	0.000584	CcSEcCtD
Rasagiline—Neuropathy peripheral—Epirubicin—uterine cancer	0.000319	0.000583	CcSEcCtD
Rasagiline—Jaundice—Epirubicin—uterine cancer	0.000317	0.00058	CcSEcCtD
Rasagiline—Stomatitis—Epirubicin—uterine cancer	0.000317	0.00058	CcSEcCtD
Rasagiline—Constipation—Etoposide—uterine cancer	0.000317	0.000579	CcSEcCtD
Rasagiline—Conjunctivitis—Epirubicin—uterine cancer	0.000317	0.000578	CcSEcCtD
Rasagiline—Dysuria—Doxorubicin—uterine cancer	0.000316	0.000577	CcSEcCtD
Rasagiline—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000314	0.000574	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—CYP11A1—uterine cancer	0.000314	0.00129	CbGpPWpGaD
Rasagiline—Sweating—Epirubicin—uterine cancer	0.000312	0.00057	CcSEcCtD
Rasagiline—Pollakiuria—Doxorubicin—uterine cancer	0.000312	0.00057	CcSEcCtD
Rasagiline—Haematuria—Epirubicin—uterine cancer	0.00031	0.000567	CcSEcCtD
Rasagiline—CYP1A2—Metapathway biotransformation—CYP11A1—uterine cancer	0.000309	0.00127	CbGpPWpGaD
Rasagiline—Photosensitivity reaction—Doxorubicin—uterine cancer	0.000308	0.000564	CcSEcCtD
Rasagiline—Epistaxis—Epirubicin—uterine cancer	0.000307	0.000561	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—TP53—uterine cancer	0.000307	0.00126	CbGpPWpGaD
Rasagiline—Weight decreased—Doxorubicin—uterine cancer	0.000306	0.000559	CcSEcCtD
Rasagiline—Feeling abnormal—Etoposide—uterine cancer	0.000305	0.000558	CcSEcCtD
Rasagiline—MAOB—Metabolism—POLD1—uterine cancer	0.000304	0.00125	CbGpPWpGaD
Rasagiline—Nausea—Dactinomycin—uterine cancer	0.000304	0.000556	CcSEcCtD
Rasagiline—Gastrointestinal pain—Etoposide—uterine cancer	0.000303	0.000554	CcSEcCtD
Rasagiline—Infestation NOS—Doxorubicin—uterine cancer	0.000301	0.000551	CcSEcCtD
Rasagiline—Infestation—Doxorubicin—uterine cancer	0.000301	0.000551	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—uterine cancer	0.000301	0.00123	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—uterine cancer	0.000301	0.00123	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TP53—uterine cancer	0.0003	0.00123	CbGpPWpGaD
Rasagiline—Neuropathy peripheral—Doxorubicin—uterine cancer	0.000295	0.00054	CcSEcCtD
Rasagiline—Urticaria—Etoposide—uterine cancer	0.000294	0.000538	CcSEcCtD
Rasagiline—Haemoglobin—Epirubicin—uterine cancer	0.000294	0.000537	CcSEcCtD
Rasagiline—Stomatitis—Doxorubicin—uterine cancer	0.000294	0.000537	CcSEcCtD
Rasagiline—Jaundice—Doxorubicin—uterine cancer	0.000294	0.000537	CcSEcCtD
Rasagiline—Rhinitis—Epirubicin—uterine cancer	0.000293	0.000535	CcSEcCtD
Rasagiline—Body temperature increased—Etoposide—uterine cancer	0.000293	0.000535	CcSEcCtD
Rasagiline—Abdominal pain—Etoposide—uterine cancer	0.000293	0.000535	CcSEcCtD
Rasagiline—Conjunctivitis—Doxorubicin—uterine cancer	0.000293	0.000535	CcSEcCtD
Rasagiline—Haemorrhage—Epirubicin—uterine cancer	0.000292	0.000534	CcSEcCtD
Rasagiline—CYP1A2—Metapathway biotransformation—AKR1C3—uterine cancer	0.000292	0.0012	CbGpPWpGaD
Rasagiline—Hypoaesthesia—Epirubicin—uterine cancer	0.000291	0.000531	CcSEcCtD
Rasagiline—Sweating—Doxorubicin—uterine cancer	0.000289	0.000528	CcSEcCtD
Rasagiline—Urinary tract disorder—Epirubicin—uterine cancer	0.000289	0.000527	CcSEcCtD
Rasagiline—Oedema peripheral—Epirubicin—uterine cancer	0.000288	0.000526	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—FGFR2—uterine cancer	0.000287	0.00118	CbGpPWpGaD
Rasagiline—Haematuria—Doxorubicin—uterine cancer	0.000287	0.000525	CcSEcCtD
Rasagiline—Connective tissue disorder—Epirubicin—uterine cancer	0.000287	0.000525	CcSEcCtD
Rasagiline—Urethral disorder—Epirubicin—uterine cancer	0.000287	0.000524	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	0.000286	0.00117	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—AKR1C1—uterine cancer	0.000284	0.00117	CbGpPWpGaD
Rasagiline—Epistaxis—Doxorubicin—uterine cancer	0.000284	0.000519	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.000279	0.00114	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IRF1—uterine cancer	0.000274	0.00112	CbGpPWpGaD
Rasagiline—Eye disorder—Epirubicin—uterine cancer	0.000273	0.000499	CcSEcCtD
Rasagiline—Hypersensitivity—Etoposide—uterine cancer	0.000273	0.000499	CcSEcCtD
Rasagiline—Haemoglobin—Doxorubicin—uterine cancer	0.000272	0.000497	CcSEcCtD
Rasagiline—Cardiac disorder—Epirubicin—uterine cancer	0.000271	0.000496	CcSEcCtD
Rasagiline—Rhinitis—Doxorubicin—uterine cancer	0.000271	0.000495	CcSEcCtD
Rasagiline—Haemorrhage—Doxorubicin—uterine cancer	0.00027	0.000494	CcSEcCtD
Rasagiline—Hypoaesthesia—Doxorubicin—uterine cancer	0.000269	0.000492	CcSEcCtD
Rasagiline—Urinary tract disorder—Doxorubicin—uterine cancer	0.000267	0.000488	CcSEcCtD
Rasagiline—Oedema peripheral—Doxorubicin—uterine cancer	0.000266	0.000487	CcSEcCtD
Rasagiline—Asthenia—Etoposide—uterine cancer	0.000266	0.000486	CcSEcCtD
Rasagiline—Connective tissue disorder—Doxorubicin—uterine cancer	0.000266	0.000486	CcSEcCtD
Rasagiline—Angiopathy—Epirubicin—uterine cancer	0.000265	0.000485	CcSEcCtD
Rasagiline—Urethral disorder—Doxorubicin—uterine cancer	0.000265	0.000484	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—uterine cancer	0.000264	0.00108	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—EP300—uterine cancer	0.000264	0.00108	CbGpPWpGaD
Rasagiline—Immune system disorder—Epirubicin—uterine cancer	0.000264	0.000482	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—PIK3CA—uterine cancer	0.000264	0.00108	CbGpPWpGaD
Rasagiline—Mediastinal disorder—Epirubicin—uterine cancer	0.000263	0.000481	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	0.000263	0.00108	CbGpPWpGaD
Rasagiline—Chills—Epirubicin—uterine cancer	0.000262	0.000479	CcSEcCtD
Rasagiline—Pruritus—Etoposide—uterine cancer	0.000262	0.000479	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—AKT1—uterine cancer	0.000259	0.00106	CbGpPWpGaD
Rasagiline—Alopecia—Epirubicin—uterine cancer	0.000258	0.000472	CcSEcCtD
Rasagiline—Mental disorder—Epirubicin—uterine cancer	0.000256	0.000468	CcSEcCtD
Rasagiline—Malnutrition—Epirubicin—uterine cancer	0.000254	0.000465	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	0.000254	0.00104	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—AKT1—uterine cancer	0.000254	0.00104	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—RRM2—uterine cancer	0.000254	0.00104	CbGpPWpGaD
Rasagiline—Diarrhoea—Etoposide—uterine cancer	0.000253	0.000463	CcSEcCtD
Rasagiline—Eye disorder—Doxorubicin—uterine cancer	0.000253	0.000462	CcSEcCtD
Rasagiline—Cardiac disorder—Doxorubicin—uterine cancer	0.000251	0.000459	CcSEcCtD
Rasagiline—Flatulence—Epirubicin—uterine cancer	0.000251	0.000458	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—uterine cancer	0.00025	0.00103	CbGpPWpGaD
Rasagiline—Dysgeusia—Epirubicin—uterine cancer	0.000249	0.000455	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—uterine cancer	0.000247	0.00101	CbGpPWpGaD
Rasagiline—Back pain—Epirubicin—uterine cancer	0.000246	0.00045	CcSEcCtD
Rasagiline—MAOB—Metabolism—DCN—uterine cancer	0.000246	0.00101	CbGpPWpGaD
Rasagiline—Angiopathy—Doxorubicin—uterine cancer	0.000245	0.000448	CcSEcCtD
Rasagiline—BCL2—Immune System—FBXW7—uterine cancer	0.000245	0.001	CbGpPWpGaD
Rasagiline—Dizziness—Etoposide—uterine cancer	0.000245	0.000448	CcSEcCtD
Rasagiline—Muscle spasms—Epirubicin—uterine cancer	0.000245	0.000447	CcSEcCtD
Rasagiline—Immune system disorder—Doxorubicin—uterine cancer	0.000244	0.000446	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—HRAS—uterine cancer	0.000244	0.001	CbGpPWpGaD
Rasagiline—Mediastinal disorder—Doxorubicin—uterine cancer	0.000244	0.000445	CcSEcCtD
Rasagiline—Chills—Doxorubicin—uterine cancer	0.000243	0.000443	CcSEcCtD
Rasagiline—Alopecia—Doxorubicin—uterine cancer	0.000239	0.000437	CcSEcCtD
Rasagiline—Mental disorder—Doxorubicin—uterine cancer	0.000237	0.000433	CcSEcCtD
Rasagiline—Ill-defined disorder—Epirubicin—uterine cancer	0.000236	0.000431	CcSEcCtD
Rasagiline—Vomiting—Etoposide—uterine cancer	0.000236	0.00043	CcSEcCtD
Rasagiline—Malnutrition—Doxorubicin—uterine cancer	0.000235	0.00043	CcSEcCtD
Rasagiline—Anaemia—Epirubicin—uterine cancer	0.000235	0.00043	CcSEcCtD
Rasagiline—Agitation—Epirubicin—uterine cancer	0.000234	0.000427	CcSEcCtD
Rasagiline—Rash—Etoposide—uterine cancer	0.000234	0.000427	CcSEcCtD
Rasagiline—Dermatitis—Etoposide—uterine cancer	0.000233	0.000426	CcSEcCtD
Rasagiline—Headache—Etoposide—uterine cancer	0.000232	0.000424	CcSEcCtD
Rasagiline—Flatulence—Doxorubicin—uterine cancer	0.000232	0.000424	CcSEcCtD
Rasagiline—MAOB—Metabolism—CYP11A1—uterine cancer	0.000232	0.00095	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—CYP19A1—uterine cancer	0.000231	0.000946	CbGpPWpGaD
Rasagiline—Dysgeusia—Doxorubicin—uterine cancer	0.000231	0.000421	CcSEcCtD
Rasagiline—Malaise—Epirubicin—uterine cancer	0.000229	0.000419	CcSEcCtD
Rasagiline—Vertigo—Epirubicin—uterine cancer	0.000229	0.000418	CcSEcCtD
Rasagiline—Syncope—Epirubicin—uterine cancer	0.000228	0.000417	CcSEcCtD
Rasagiline—Leukopenia—Epirubicin—uterine cancer	0.000228	0.000416	CcSEcCtD
Rasagiline—Back pain—Doxorubicin—uterine cancer	0.000228	0.000416	CcSEcCtD
Rasagiline—CYP1A2—Metapathway biotransformation—CYP19A1—uterine cancer	0.000228	0.000933	CbGpPWpGaD
Rasagiline—Muscle spasms—Doxorubicin—uterine cancer	0.000226	0.000414	CcSEcCtD
Rasagiline—Loss of consciousness—Epirubicin—uterine cancer	0.000224	0.000409	CcSEcCtD
Rasagiline—Cough—Epirubicin—uterine cancer	0.000222	0.000406	CcSEcCtD
Rasagiline—Convulsion—Epirubicin—uterine cancer	0.00022	0.000403	CcSEcCtD
Rasagiline—Nausea—Etoposide—uterine cancer	0.00022	0.000402	CcSEcCtD
Rasagiline—Hypertension—Epirubicin—uterine cancer	0.00022	0.000401	CcSEcCtD
Rasagiline—MAOB—Metabolism—AKR1C3—uterine cancer	0.000219	0.000897	CbGpPWpGaD
Rasagiline—Ill-defined disorder—Doxorubicin—uterine cancer	0.000218	0.000399	CcSEcCtD
Rasagiline—Anaemia—Doxorubicin—uterine cancer	0.000218	0.000398	CcSEcCtD
Rasagiline—Chest pain—Epirubicin—uterine cancer	0.000217	0.000396	CcSEcCtD
Rasagiline—Arthralgia—Epirubicin—uterine cancer	0.000217	0.000396	CcSEcCtD
Rasagiline—Agitation—Doxorubicin—uterine cancer	0.000216	0.000395	CcSEcCtD
Rasagiline—Anxiety—Epirubicin—uterine cancer	0.000216	0.000394	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—AKT1—uterine cancer	0.000216	0.000883	CbGpPWpGaD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000215	0.000393	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	0.000215	0.00088	CbGpPWpGaD
Rasagiline—Discomfort—Epirubicin—uterine cancer	0.000214	0.000391	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—uterine cancer	0.000213	0.000872	CbGpPWpGaD
Rasagiline—Malaise—Doxorubicin—uterine cancer	0.000212	0.000388	CcSEcCtD
Rasagiline—Dry mouth—Epirubicin—uterine cancer	0.000212	0.000387	CcSEcCtD
Rasagiline—Vertigo—Doxorubicin—uterine cancer	0.000212	0.000387	CcSEcCtD
Rasagiline—Syncope—Doxorubicin—uterine cancer	0.000211	0.000386	CcSEcCtD
Rasagiline—Leukopenia—Doxorubicin—uterine cancer	0.000211	0.000385	CcSEcCtD
Rasagiline—Confusional state—Epirubicin—uterine cancer	0.000209	0.000383	CcSEcCtD
Rasagiline—Loss of consciousness—Doxorubicin—uterine cancer	0.000207	0.000378	CcSEcCtD
Rasagiline—Infection—Epirubicin—uterine cancer	0.000206	0.000377	CcSEcCtD
Rasagiline—Cough—Doxorubicin—uterine cancer	0.000205	0.000375	CcSEcCtD
Rasagiline—Shock—Epirubicin—uterine cancer	0.000204	0.000373	CcSEcCtD
Rasagiline—Convulsion—Doxorubicin—uterine cancer	0.000204	0.000373	CcSEcCtD
Rasagiline—Nervous system disorder—Epirubicin—uterine cancer	0.000204	0.000372	CcSEcCtD
Rasagiline—Hypertension—Doxorubicin—uterine cancer	0.000203	0.000371	CcSEcCtD
Rasagiline—Skin disorder—Epirubicin—uterine cancer	0.000202	0.000369	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.000201	0.000825	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.000201	0.000825	CbGpPWpGaD
Rasagiline—Hyperhidrosis—Epirubicin—uterine cancer	0.000201	0.000367	CcSEcCtD
Rasagiline—BCL2—Immune System—SOCS3—uterine cancer	0.000201	0.000822	CbGpPWpGaD
Rasagiline—Chest pain—Doxorubicin—uterine cancer	0.0002	0.000366	CcSEcCtD
Rasagiline—Arthralgia—Doxorubicin—uterine cancer	0.0002	0.000366	CcSEcCtD
Rasagiline—Anxiety—Doxorubicin—uterine cancer	0.0002	0.000365	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000199	0.000364	CcSEcCtD
Rasagiline—Discomfort—Doxorubicin—uterine cancer	0.000198	0.000362	CcSEcCtD
Rasagiline—Anorexia—Epirubicin—uterine cancer	0.000198	0.000362	CcSEcCtD
Rasagiline—Dry mouth—Doxorubicin—uterine cancer	0.000196	0.000358	CcSEcCtD
Rasagiline—Hypotension—Epirubicin—uterine cancer	0.000194	0.000355	CcSEcCtD
Rasagiline—Confusional state—Doxorubicin—uterine cancer	0.000194	0.000354	CcSEcCtD
Rasagiline—Infection—Doxorubicin—uterine cancer	0.000191	0.000349	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000189	0.000346	CcSEcCtD
Rasagiline—Shock—Doxorubicin—uterine cancer	0.000189	0.000345	CcSEcCtD
Rasagiline—Nervous system disorder—Doxorubicin—uterine cancer	0.000188	0.000344	CcSEcCtD
Rasagiline—Insomnia—Epirubicin—uterine cancer	0.000188	0.000343	CcSEcCtD
Rasagiline—Skin disorder—Doxorubicin—uterine cancer	0.000187	0.000341	CcSEcCtD
Rasagiline—Paraesthesia—Epirubicin—uterine cancer	0.000186	0.000341	CcSEcCtD
Rasagiline—Hyperhidrosis—Doxorubicin—uterine cancer	0.000186	0.000339	CcSEcCtD
Rasagiline—Dyspnoea—Epirubicin—uterine cancer	0.000185	0.000338	CcSEcCtD
Rasagiline—Somnolence—Epirubicin—uterine cancer	0.000185	0.000337	CcSEcCtD
Rasagiline—Anorexia—Doxorubicin—uterine cancer	0.000183	0.000335	CcSEcCtD
Rasagiline—Dyspepsia—Epirubicin—uterine cancer	0.000183	0.000334	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	0.000181	0.000741	CbGpPWpGaD
Rasagiline—Decreased appetite—Epirubicin—uterine cancer	0.000181	0.00033	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—ERBB2—uterine cancer	0.00018	0.000739	CbGpPWpGaD
Rasagiline—Hypotension—Doxorubicin—uterine cancer	0.00018	0.000328	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000179	0.000328	CcSEcCtD
Rasagiline—Constipation—Epirubicin—uterine cancer	0.000178	0.000324	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000175	0.00032	CcSEcCtD
Rasagiline—Insomnia—Doxorubicin—uterine cancer	0.000174	0.000318	CcSEcCtD
Rasagiline—Paraesthesia—Doxorubicin—uterine cancer	0.000173	0.000315	CcSEcCtD
Rasagiline—Dyspnoea—Doxorubicin—uterine cancer	0.000171	0.000313	CcSEcCtD
Rasagiline—Feeling abnormal—Epirubicin—uterine cancer	0.000171	0.000313	CcSEcCtD
Rasagiline—Somnolence—Doxorubicin—uterine cancer	0.000171	0.000312	CcSEcCtD
Rasagiline—MAOB—Metabolism—STK11—uterine cancer	0.000171	0.000699	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CYP19A1—uterine cancer	0.000171	0.000699	CbGpPWpGaD
Rasagiline—Gastrointestinal pain—Epirubicin—uterine cancer	0.00017	0.00031	CcSEcCtD
Rasagiline—Dyspepsia—Doxorubicin—uterine cancer	0.000169	0.000309	CcSEcCtD
Rasagiline—BCL2—Immune System—FGFR2—uterine cancer	0.000167	0.000685	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CDKN1B—uterine cancer	0.000167	0.000684	CbGpPWpGaD
Rasagiline—Decreased appetite—Doxorubicin—uterine cancer	0.000167	0.000305	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000166	0.000303	CcSEcCtD
Rasagiline—Urticaria—Epirubicin—uterine cancer	0.000165	0.000301	CcSEcCtD
Rasagiline—Constipation—Doxorubicin—uterine cancer	0.000164	0.0003	CcSEcCtD
Rasagiline—Body temperature increased—Epirubicin—uterine cancer	0.000164	0.0003	CcSEcCtD
Rasagiline—Abdominal pain—Epirubicin—uterine cancer	0.000164	0.0003	CcSEcCtD
Rasagiline—Feeling abnormal—Doxorubicin—uterine cancer	0.000158	0.000289	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—CTNNB1—uterine cancer	0.000158	0.000647	CbGpPWpGaD
Rasagiline—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000157	0.000287	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—PTEN—uterine cancer	0.000154	0.00063	CbGpPWpGaD
Rasagiline—Hypersensitivity—Epirubicin—uterine cancer	0.000153	0.00028	CcSEcCtD
Rasagiline—Urticaria—Doxorubicin—uterine cancer	0.000153	0.000279	CcSEcCtD
Rasagiline—Body temperature increased—Doxorubicin—uterine cancer	0.000152	0.000278	CcSEcCtD
Rasagiline—Abdominal pain—Doxorubicin—uterine cancer	0.000152	0.000278	CcSEcCtD
Rasagiline—Asthenia—Epirubicin—uterine cancer	0.000149	0.000272	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	0.000148	0.000606	CbGpPWpGaD
Rasagiline—Pruritus—Epirubicin—uterine cancer	0.000147	0.000268	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—EP300—uterine cancer	0.000147	0.000601	CbGpPWpGaD
Rasagiline—Diarrhoea—Epirubicin—uterine cancer	0.000142	0.00026	CcSEcCtD
Rasagiline—Hypersensitivity—Doxorubicin—uterine cancer	0.000142	0.000259	CcSEcCtD
Rasagiline—Asthenia—Doxorubicin—uterine cancer	0.000138	0.000252	CcSEcCtD
Rasagiline—Dizziness—Epirubicin—uterine cancer	0.000137	0.000251	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—NRAS—uterine cancer	0.000137	0.000562	CbGpPWpGaD
Rasagiline—Pruritus—Doxorubicin—uterine cancer	0.000136	0.000248	CcSEcCtD
Rasagiline—Vomiting—Epirubicin—uterine cancer	0.000132	0.000241	CcSEcCtD
Rasagiline—Diarrhoea—Doxorubicin—uterine cancer	0.000131	0.00024	CcSEcCtD
Rasagiline—Rash—Epirubicin—uterine cancer	0.000131	0.000239	CcSEcCtD
Rasagiline—Dermatitis—Epirubicin—uterine cancer	0.000131	0.000239	CcSEcCtD
Rasagiline—Headache—Epirubicin—uterine cancer	0.00013	0.000238	CcSEcCtD
Rasagiline—MAOB—Metabolism—MTHFR—uterine cancer	0.000128	0.000525	CbGpPWpGaD
Rasagiline—Dizziness—Doxorubicin—uterine cancer	0.000127	0.000232	CcSEcCtD
Rasagiline—BCL2—Immune System—CDH1—uterine cancer	0.000125	0.00051	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SRD5A2—uterine cancer	0.000124	0.000508	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NDUFB11—uterine cancer	0.000124	0.000508	CbGpPWpGaD
Rasagiline—Nausea—Epirubicin—uterine cancer	0.000123	0.000225	CcSEcCtD
Rasagiline—Vomiting—Doxorubicin—uterine cancer	0.000122	0.000223	CcSEcCtD
Rasagiline—Rash—Doxorubicin—uterine cancer	0.000121	0.000221	CcSEcCtD
Rasagiline—Dermatitis—Doxorubicin—uterine cancer	0.000121	0.000221	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	0.00012	0.000494	CbGpPWpGaD
Rasagiline—Headache—Doxorubicin—uterine cancer	0.00012	0.00022	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—KRAS—uterine cancer	0.000118	0.000484	CbGpPWpGaD
Rasagiline—Nausea—Doxorubicin—uterine cancer	0.000114	0.000209	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	0.000114	0.000466	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PIK3CA—uterine cancer	0.000109	0.000445	CbGpPWpGaD
Rasagiline—BCL2—Immune System—ERBB2—uterine cancer	0.000105	0.00043	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—HRAS—uterine cancer	0.0001	0.000411	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CDKN1B—uterine cancer	9.73e-05	0.000399	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CTNNB1—uterine cancer	9.19e-05	0.000377	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—STAR—uterine cancer	8.97e-05	0.000367	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—AKR1B1—uterine cancer	8.97e-05	0.000367	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PTEN—uterine cancer	8.96e-05	0.000367	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—AKT1—uterine cancer	8.87e-05	0.000363	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	8.87e-05	0.000363	CbGpPWpGaD
Rasagiline—BCL2—Immune System—EP300—uterine cancer	8.55e-05	0.00035	CbGpPWpGaD
Rasagiline—BCL2—Immune System—NRAS—uterine cancer	7.99e-05	0.000327	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PTEN—uterine cancer	7.13e-05	0.000292	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—POLD1—uterine cancer	7.04e-05	0.000288	CbGpPWpGaD
Rasagiline—BCL2—Immune System—KRAS—uterine cancer	6.88e-05	0.000282	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—EP300—uterine cancer	6.8e-05	0.000279	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—AKR1C1—uterine cancer	6.58e-05	0.00027	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PIK3CA—uterine cancer	6.32e-05	0.000259	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—RRM2—uterine cancer	5.87e-05	0.00024	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HRAS—uterine cancer	5.85e-05	0.00024	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—DCN—uterine cancer	5.7e-05	0.000233	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP11A1—uterine cancer	5.37e-05	0.00022	CbGpPWpGaD
Rasagiline—BCL2—Immune System—AKT1—uterine cancer	5.16e-05	0.000212	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—AKR1C3—uterine cancer	5.07e-05	0.000208	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CA—uterine cancer	5.03e-05	0.000206	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—AKT1—uterine cancer	4.11e-05	0.000168	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—STK11—uterine cancer	3.95e-05	0.000162	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP19A1—uterine cancer	3.95e-05	0.000162	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	3.71e-05	0.000152	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	3.53e-05	0.000145	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—MTHFR—uterine cancer	2.97e-05	0.000122	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.61e-05	0.000107	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PTEN—uterine cancer	1.65e-05	6.76e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—EP300—uterine cancer	1.57e-05	6.45e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CA—uterine cancer	1.16e-05	4.77e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—AKT1—uterine cancer	9.51e-06	3.9e-05	CbGpPWpGaD
